Disease mutations in Rab7 result in unregulated nucleotide exchange and inappropriate activation

Brett A. McCray1,2, Emmanuel Skordalakes3 and J. Paul Taylor1,*

1Department of Developmental Neurobiology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA, 2Neuroscience Graduate Group, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA and 3Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104, USA

Received October 7, 2009; Revised November 23, 2009; Accepted December 21, 2009

Rab GTPases are molecular switches that orchestrate vesicular trafficking, maturation and fusion by cycling between an active, GTP-bound form, and an inactive, GDP-bound form. The activity cycle is coupled to GTP hydrolysis and is tightly controlled by regulatory proteins. Missense mutations of the GTPase Rab7 cause a dominantly inherited axonal degeneration known as Charcot-Marie-Tooth type 2B through an unknown mechanism. We present the 2.8 Å crystal structure of GTP-bound L129F mutant Rab7 which reveals normal conformations of the effector binding regions and catalytic site, but an alteration to the nucleotide binding pocket that is predicted to alter GTP binding. Through extensive biochemical analysis, we demonstrate that disease-associated mutations in Rab7 do not lead to an intrinsic GTPase defect, but permit unregulated nucleotide exchange leading to both excessive activation and hydrolysis-independent inactivation. Consistent with augmented activity, mutant Rab7 shows significantly enhanced interaction with a subset of effector proteins. In addition, dynamic imaging demonstrates that mutant Rab7 is abnormally retained on target membranes. However, we show that the increased activation of mutant Rab7 is counterbalanced by unregulated, GTP hydrolysis-independent membrane cycling. Notably, disease mutations are able to rescue the membrane cycling of a GTPase-deficient mutant. Thus, we demonstrate that disease mutations uncouple Rab7 from the spatial and temporal control normally imposed by regulatory proteins and cause disease not by a gain of novel toxic function, but by misregulation of native Rab7 activity.

INTRODUCTION

Members of the Rab family of small GTPases such as Rab7 are master regulators of vesicular trafficking, maturation and fusion. Rab GTPases function as molecular switches by cycling between active, GTP-bound states in which they are reversibly associated with specific vesicular membranes and inactive, GDP-bound states in which they are predominantly cytosolic and dissociated from their target membranes. Following GTP binding, Rabs recruit specific effector proteins that are involved in vesicular transport and hetero- and homotypic fusion events. For each of the more than 60 human Rabs, multiple regulatory proteins have evolved to modulate Rab membrane targeting and activity. Inactive Rabs are largely sequestered in the cytosol by Rab GDP-dissociation inhibitor (GDI) which recognizes GDP-bound Rabs and binds their C-terminal geranylgeranyl group (1,2). Activation of Rabs requires extraction from Rab GDI, insertion into membranes and GTP exchange. To facilitate GTP exchange, guanine nucleotide exchange factors (GEFs) bind the GDP-bound conformation of Rabs and lead to structural alterations that facilitate GDP release and allow subsequent GTP binding (3). Two ‘switch’ regions of Rabs undergo conformational changes depending on the identity of the bound guanine nucleotide. Rab effector proteins specifically recognize the GTP-bound conformation of the switch regions and are therefore recruited only to activate Rabs. Termination of Rab function is mediated through hydrolysis of the γ-phosphate of GTP to yield GDP. GTPase activating proteins (GAPs) accelerate the hydrolysis reaction by catalyzing the nucleophilic attack

*To whom correspondence should be addressed at: Department of Developmental Neurobiology, St Jude Children’s Research Hospital, 262 Danny Thomas Place, MS 343, D-4026, Memphis, TN 38105-3678, USA. Tel: +1 9015956047; Fax: +1 9015952032; Email: jpaul.taylor@stjude.org

© The Author 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
of a water molecule on the $\gamma$-phosphate of GTP. Following hydrolysis, GDP-bound Rabs are recognized and extracted from the membrane by GDI (4). Thus, GEF and GAP proteins along with GDI play a critical role in the regulation of the Rab activity cycle.

Rab7 is a ubiquitously expressed protein that plays a vital role in the regulation of the trafficking, maturation and fusion of endocytic and autophagic vesicles. Rab7 localizes primarily to acidic, pre-degradative and degradative organelles such as late endosomes, lysosomes, multivesicular bodies, phagosomes, autophagosomes and autophagolysosomes (5–8). Rab7 specifically controls the transition of early endosomes into the late-endosomal/lysosomal system and subsequent degradation of cargos associated with target vesicles. As such, Rab7 activity regulates the lysosome-mediated degradation of endocytic cargos such as activated EGF receptors, internalized cholesterol and neurotrophic factor receptors such as TrkA (6,9,10). In addition, fusion of autophagic vacuoles with lysosomes requires Rab7 activity (11,12). Rab7 has also been implicated in the regulation of long-range axonal trafficking (13). Although there is no consensus as to the exact role of Rab7 in axonal transport, evidence suggests that Rab5 and Rab7 together regulate the retrograde trafficking of signaling endosomes that supply trophic support to neurons in the peripheral nervous system (14).

Charcot-Marie-Tooth disease comprises a heterogeneous group of inherited peripheral neuropathies (15). Patients with CMT present with length-dependent sensory, motor or autonomic dysfunction either alone or in combination. Two major subtypes of CMT are recognized and distinguished by the primary pathology. CMT type 1 is characterized by prominent demyelination and decreased nerve conduction velocities and is most commonly caused by mutations in myelin-specific proteins. In contrast, the primary pathological feature in CMT type 2 is axonal degeneration. Although genetic mutations that cause CMT type 2 affect a variety of cellular processes, defects in mitochondrial physiology, chaperone activity and axonal transport pathways are most commonly implicated (16). To date, four missense mutations in Rab7 have been associated with Charcot-Marie-Tooth disease type 2B (OMIM 600882) (17–19). This subtype of CMT is distinguished by profound loss of pain sensation leading to recurrent ulcers, deformities and frequent need for amputation of the lower limbs (20). As such, CMT2B is alternatively classified as ulcero-mutilating neuropathy. Degeneration of motor neurons and subsequent muscle weakness are also associated with CMT2B (20).

At present, it is unknown how mutations in Rab7 lead to axonal degeneration. A prior study suggested that disease mutations reduce nucleotide affinity, impair Rab7 GTPase activity and lead to constitutive activation (21). However, the finding of decreased hydrolysis in disease mutants was enigmatic given that the mutations are not localized near the catalytic site. Therefore, we set out to precisely define the impact of disease-causing mutations on Rab7 structure and function in order to illuminate the mechanism of pathogenesis. We determined the crystal structure of GTP-bound L129F mutant Rab7 at 2.8 Å resolution revealing an alteration to the nucleotide binding pocket, but no impact on the catalytic region of Rab7. These findings guided biochemical analyses in which we determined that disease-causing mutations in Rab7 do not lead to an intrinsic GTPase defect, but instead result in decreased nucleotide affinity and permit unregulated nucleotide exchange. We report that misregulation of Rab7 activation results in an increase in the active fraction of Rab7 and abnormal retention on target membranes. However, we also show that the excessive activation of Rab7 mutants is counterbalanced by unregulated, GTP hydrolysis-independent cycling, thus ruling out constitutive activation of mutant Rab7 as a pathogenic mechanism for CMT2B. We also used an unbiased approach to interrogate the protein interactors of wild-type and mutant forms of Rab7. As predicted by our structural data, the complement of interactors in wild-type and mutant Rab7 is qualitatively identical, although there is significantly enhanced interaction of mutant Rab7 with a subset of effectors proteins. This study reveals a pathogenic mechanism wherein disease mutations uncouple Rab7 from normal spatial and temporal regulatory restraints resulting in toxic misregulation of Rab7 activity.

RESULTS

The L129F mutation alters the nucleotide binding pocket of Rab7

Rab GTPases cycle between active, GTP-bound, membrane-associated states and inactive, GDP-bound, cytosolic states. Mutations in Rab7 that cause CMT2B cluster near the highly conserved G-loops that are involved in nucleotide binding. A previous study demonstrated decreased GTP hydrolysis in disease mutants (21). However, as residues mutated in CMT2B are not near the catalytic glutamine (Q67) or the hydrolyzed $\gamma$-phosphate of GTP, it was unclear how disease mutations could impair GTPase activity. To resolve this issue and provide mechanistic insight into CMT2B, we solved the crystal structure of the L129F Rab7 mutant in its active, GTP-bound form. The structure of full-length L129F Rab7 bound to the non-hydrolysable GTP analog GppNHp was solved to 2.8 Å by molecular replacement (MR) using wild-type Rab7 as a search model (Table 1). The L129F substitution does not alter the overall structure of the molecule as compared to the published structure of wild-type Rab7 bound to GppNHp (PDB 1VG8) (Fig. 1A–C, Supplementary Material, Fig. S1 for stereo views) (22). Notably, the conformation of the effector binding switch region of the protein closely approximates that of wild-type Rab7 and is therefore not predicted to alter effector binding. Furthermore, the catalytic glutamine (Q67) and the position of the $\gamma$-phosphate group of GppNHp were not significantly altered, providing no structural basis to predict decreased intrinsic GTPase activity (Fig. 1D, Supplementary Material, Fig. S2 for an omit map of the nucleotide binding pocket). However, L129F substitution enlarges the hydrophobic group that lies adjacent to the guanine ring of GTP and leads to steric hindrance and subtle repositioning (~0.6 Å) of the guanine ring away from F129 (Fig. 1D–F, Supplementary Material, Fig. S3 for stereo views). This also slightly modifies the position of the invariant D128 and
K157 residues that are directly involved in nucleotide binding (Fig. 1D). Of particular note is the repositioning of the carboxylate group of D128, which in the wild-type Rab7 makes pseudo Watson–Crick pairing interactions with the guanine base of the nucleotide. In L129F, this interaction appears to be partially altered leading to longer hydrogen bonds and in some cases (we have five molecules in the asymmetric unit and therefore five independent observations) complete disruption of one of the two hydrogen bonds. We predicted that these changes would alter affinity for guanine nucleotides and affect the rates of dissociation for GTP and/or GDP. Interestingly, K157, which is also directly involved in nucleotide binding and is shifted in the L129F mutant structure, is mutated to asparagine in a patient with CMT2B (19).

### Mutant Rab7 has decreased nucleotide affinity, but no intrinsic GTPase defect

To determine how the steric hindrance imposed by the L129F mutation affects guanine nucleotide binding, we performed GTP and GDP dissociation assays using purified recombinant wild-type and L129F Rab7. We also analyzed the V162M mutant to determine whether there are consistent biochemical alterations among different disease-causing Rab7 mutants. Recombinant Rab7 proteins were loaded with \(^{3}H\)-GTP or \(^{3}H\)-GDP and the dissociation of nucleotide was followed over time. We found that Rab7 mutants have an increased rate of GTP dissociation relative to wild-type (Fig. 2A), and an even more rapid rate of GDP dissociation with almost complete dissociation within 15 min (Fig. 2B). These results are consistent with the previous work showing increased dissociation of guanine nucleotides in Rab7 disease mutants (21). In Rab7 mutants, ~70% of initially bound GTP dissociated over the course of 60 min.

Although Rab7 disease mutants were previously reported to have nearly complete loss of GTPase activity (21), we found no structural basis for altered GTP hydrolysis in the L129F mutant. To account for this discrepancy, we hypothesized that reduced hydrolysis might reflect increased rates of GTP dissociation rather than an intrinsic catalytic defect. To test this idea, we first performed GTPase assays using purified recombinant Rab7 as previously described (21). When Rab7 was loaded with \(^{32}P\)-GTP and hydrolysis was initiated in the presence of excess unlabeled GTP, we saw a marked decrease in GTP hydrolysis in the L129F mutant that was similar to the Q67L mutant which contains a targeted disruption of the catalytic residue (Fig. 2C and D, left). However, this assay specifically measures the rate of GTP hydrolysis per GTP binding event, because re-association of \(^{32}P\)-GTP is effectively precluded by the excess unlabeled GTP. We predicted that if we performed the assay with excess \(^{32}P\)-GTP and no unlabeled GDP, we could counteract the effect of decreased nucleotide affinity by allowing for dissociation and re-association of radiolabeled GTP. Indeed, we found that the apparent GTPase defect in the L129F mutant could be partially rescued by omitting excess unlabeled GTP from the reaction, whereas this modification had no effect on the Q67L mutant (Fig. 2C, right and D). Furthermore, increasing the concentration of \(^{32}P\)-GTP further restored catalytic activity (Fig. 2E), indicating that dissociation and re-association of GTP happens rapidly in disease mutants and that catalytic activity of L129F Rab7 approaches that of wild-type Rab7. Thus, when GTP is in constant supply (as is the case in vivo), catalytic activity in disease mutants is not significantly impaired, and decreased GTP hydrolysis cannot account for the defects seen in mutant Rab7.

### Mutant Rab7 undergoes GEF-independent nucleotide exchange and excessive activation

Normally, GDP is tightly bound by Rab GTPases, and the low intrinsic rate of GDP dissociation makes GDP release the rate-limiting step of nucleotide exchange and Rab activation. GEF proteins have evolved to facilitate GDP dissociation and the subsequent GTP loading of Rab proteins. Given the rapid rate of GDP dissociation in the Rab7 disease mutants, we hypothesized that nucleotide exchange might be misregulated and occur independent of GEF activity. To test this hypothesis, we interrogated GTP exchange rates using purified, recombinant Rab7 proteins in the absence of any GEF activity. First, we determined that Rab7 wild-type and disease mutants bound roughly the same amount of GTP following stripping of endogenous bound nucleotide (Fig. 3A). Next, we tested GTP exchange by stripping endogenous nucleotide, then pre-loading the Rab7 proteins with GDP before incubation with \(^{3}H\)-GTP. In this assay, \(^{3}H\)-GTP binding requires dissociation of the pre-loaded GDP and thus represents the rate of GTP exchange. The amount of \(^{3}H\)-GTP bound was compared with the maximum amount that could be bound without GDP pre-incubation. As expected, wild-type Rab7 showed a slow rate of GTP exchange in the absence of GEF activity (only 10–20% of maximal binding). However, disease-causing

| Data collection          |  
|--------------------------|
| Space group              | P1  
| Cell dimensions (a, b, c in Å) | 35.6, 89.33, 89.38  
| Resolution (Å)           | 20–2.8 (2.9–2.8)  
| R<sub>sym</sub> or R<sub>merge</sub> | 10.0 (41.7)  
| I/σI                      | 7.7 (1.7)  
| Completeness (%)          | 98.7 (98.2)  
| Redundancy                | 2 (2)  
| Refinement               |  
| Resolution (Å)           | 20–2.8  
| No. unique reflections   | 27713  
| R<sub>merge</sub>/R<sub>free</sub> | 25.5/27.1  
| No. atoms                | 6925  
| Protein                  | 6925  
| Ligands                  | 155  
| Ions                     | 5  
| Water                    | 45  
| R.m.s. deviations Bond lengths (Å) | 0.011  
| Bond angles (°)          | 1.16  
| Ramachandran plot (%)    |  
| Most favored             | 87.6  
| Allowed                  | 10.9  
| Generously allowed       | 1.2  
| Disallowed               | 0.2  

<sup>a</sup>Highest resolution shell shown in parentheses.
Rab7 mutants underwent GTP exchange significantly faster, achieving nearly 60% of maximal binding over 30 min (Fig. 3B). This suggests that GTP exchange in Rab7 mutants can occur in an unregulated, GEF-independent manner. To determine whether GTP exchange is also misregulated in a cellular context, we tested the ability of immunopurified Rab7 complexes to undergo guanine nucleotide exchange. FLAG–Rab7 was immunopurified from HEK293T cell lysates and then incubated with 3H-GTP. As in the cell-free system, Rab7 mutants were able to undergo nucleotide exchange.
exchange more readily than wild-type Rab7 despite equal immunoprecipitation of Rab7 in each condition (Fig. 3C).

These results indicate that the structural changes imposed by the L129F and V162M mutations lead to misregulation of GTP exchange and inappropriate activation of Rab7 mutants. Augmented GTP exchange in the disease mutants would be predicted to shift the ratio of the GTP and GDP-bound fractions of Rab7 in cells. To test this, we performed pull-down assays using an immobilized Rab7 binding region of the Rab7 effector Rab-interacting lysosomal protein (RILP) and lysates from HEK293T cells expressing GFP–Rab7 (23). As RILP specifically binds GTP-bound Rab7, the amount of Rab7 associated with RILP in this assay represents the GTP-bound fraction. GST-RILP showed increased interaction with the predominantly GTP-bound, GTPase-deficient Q67L mutant and no interaction with the GTP-binding deficient T22N mutant, indicating that this experiment accurately reflects changes in the active pool of Rab7 (Fig. 3D). The amount of Rab7 disease-causing mutants pulled down by GST-RILP was significantly increased compared with wild-type Rab7 (Fig. 3D and E). This finding indicates that accelerated GTP exchange in disease mutants leads to an increase in the active, GTP-bound fraction of Rab7.

Disease-causing mutations cause quantitative changes in Rab7 interactions

To more broadly address the impact of disease-causing Rab7 mutations on interaction with binding partners, we used an unbiased proteomics approach to examine the protein–protein interactions in wild-type and mutant Rab7. Rab7 effectors specifically recognize the switch regions when Rab GTPases are in the GTP-bound conformation. On the basis of the crystal structure, we predicted that the L129F Rab7 mutant would interact normally with Rab7 effectors. However, as Rab7 mutations increase the fraction of Rab7 in the active conformation and cause misregulation of the Rab7 activity cycle, we predicted that there may be quantitative differences in the type of Rab7 complexes that are formed. A number of Rab7-interacting proteins have been described, including RILP, Oxysterol binding protein-related protein 1L (ORP1L), Rabring7, Rab escort protein-1 (REP-1), Rab GDI, the Vps34 subunit of PI3 kinase and members of the retromer complex (24–30).

To examine Rab7 interactors, FLAG–Rab7 complexes were immunopurified from HEK293T cell lysates, separated by SDS–PAGE and interacting proteins were then identified.
by mass spectrometry. The profiles of proteins identified in wild-type and mutant Rab7 were qualitatively identical, suggesting that Rab7 mutants bind to the same complement of interactors as wild-type Rab7 (Fig. 4A and B, Supplementary Material, Fig. S4). We identified several putative novel Rab7 interacting proteins as well as previously known Rab7 interactors (Table 2). To verify the specificity of our mass spectrometry protein identification, interactions with the known effectors RILP and GDI2 and the novel interactors VapB, SPG21, PHB and stomatin-like 2 were confirmed by coimmunoprecipitation followed by western blotting (Supplementary Material, Fig. S5).

Although the complement of effectors is largely unchanged by disease-causing mutations, we were able to detect quantitative differences in the amount of specific effectors coimmunoprecipitated with wild-type and mutant Rab7 (Fig. 4B and C). Specifically, Rab7 disease mutants L129F and V162M and the constitutively active mutant Q67L showed increased interaction with Vps13C and ORP1L, whereas only the disease mutants showed increased interaction with clathrin heavy chain, and all constructs interacted equally with REP-1 (Fig. 4C). These results suggest that the misregulation of the Rab7 activity cycle in disease mutants leads to the augmentation of specific effector interactions. Furthermore, the increased interaction with Vps13C and the GTP-dependent interactor ORP1L seen in disease mutants and in the Q67L mutant provides additional support for an increase in the active fraction of mutant Rab7.

Rab7 disease mutant localization is distinct from constitutively active Rab7

We next assessed the consequences of the structural and biochemical alterations in mutant Rab7 on membrane targeting and exchange dynamics. To determine whether disease mutations affect Rab7 subcellular localization, we analyzed the distribution of GFP-tagged Rab7 in HeLa cells. Wild-type Rab7 reversibly associates with the cytosolic face of late endosomes, lysosomes and autophagosomes and shows a diffuse vesicular pattern that largely overlaps with the...
late-endosomal/lysosomal marker LAMP2 (Fig. 5A, top) and the acidotropic dye LysoTracker Red (data not shown) as expected (6). The dominant-negative T22N mutant has a diffuse, reticular localization and leads to dispersal and altered morphology of late endosomes and lysosomes (Fig. 5A, bottom). In contrast, the constitutively active Q67L mutant Rab7 colocalizes with LAMP2, but leads to prominent accumulation of enlarged vesicles that cluster adjacent to the nucleus (Fig. 5A, middle). Surprisingly, despite evidence of unregulated activation, Rab7 disease mutants have normal subcellular localization and associate normally with LAMP2 (Fig. 5B) and LysoTracker Red (data not shown). Quantification of the cellular phenotypes verified our observation that disease mutants are similar to wild-type Rab7 and distinct from the Q67L mutant (Fig. 5C, see Supplementary Material, Fig. S6 for scoring examples). We also demonstrated that Rab7 disease mutations do not impair targeting to autophagosomes or flux through the autophagic pathway (Supplementary Material, Fig. S7). Thus, even though Rab7 disease mutants show a marked increase in the active fraction, the cellular phenotype of disease mutants is clearly distinct from the Q67L mutant (Fig. 5A–C) providing further evidence that a GTPase defect alone cannot account for the phenotype in Rab7 disease mutants.

Mutant Rab7 is abnormally retained on vesicular membranes

Rab GTPases switch between the GTP-bound state in which they are active and membrane-associated and the GDP-bound state in which they are inactive and cytosolic. Our results suggest increased activation of Rab7 disease mutants which would be predicted to correlate with alterations in the activity cycle. To assess the net impact of Rab7 mutations on membrane cycling, we used dynamic live-cell imaging to characterize wild-type and mutant GFP–Rab7 in living cells. Time-lapse images demonstrate that disease-causing mutants of Rab7 associate with vesicular structures that are highly motile and undergo multiple fusion and fission events similar to wild-type (Supplementary Material, Movies S1–S4). We next used dynamic live-cell imaging and a fluorescence recovery after photobleaching (FRAP) approach to examine how disease-causing mutations of Rab7 affect membrane cycling activity. HeLa cells were transfected with

Table 2. Proteomics summary and statistics

| Protein name          | MW (Da) | Sequence count | Coverage (%) | Novelty |
|-----------------------|---------|----------------|--------------|---------|
| GDI2                  | 51 088  | 370            | 76           |         |
| GDI1                  | 51 177  | 255            | 70           |         |
| Prohibitin (PHB2)     | 33 276  | 115            | 51           | *       |
| Prohibitin (PHB)      | 29 843  | 84             | 51           | *       |
| REP-1 (CHM)           | 74 740  | 77             | 39           |         |
| Vps13C                | 419 351 | 217            | 34           | *       |
| ORP1L                 | 109 739 | 71             | 29           |         |
| VapB (ALS8)           | 27 365  | 6              | 25           | *       |
| Stomatilike-2 (EPB72)| 35 158  | 23             | 25           | *       |
| Clathrin HC           | 193 703 | 44             | 24           | *       |
| GNB2L1 (RACK1)        | 40 193  | 7              | 18           | *       |
| ATP6V0A1              | 96 487  | 10             | 13           |         |
| Spastic paraplegia 21 | 35 223  | 7              | 12           |         |
| IMMT (Mitofilin)      | 83 669  | 10             | 9            | *       |
| RILP                  | 44 375  | 3              | 8            |         |
| ANKFY1                | 128 489 | 4              | 4            |         |

*Novel interactor.
Figure 5. Rab7 disease mutants have normal subcellular localization but decreased membrane cycling. (A-B) HeLa cells transfected with GFP–Rab7 constructs were fixed and stained with anti-LAMP2 antibody. Wild-type Rab7 and disease mutants colocalize with LAMP2-positive vesicles and do not cause any alteration in their morphology or localization. In contrast, constitutively active Q67L Rab7 causes clustering of LAMP2-positive vesicles, whereas dominant-negative T22N Rab7 leads to their dispersal and enlargement. (C) Quantification of vesicular phenotypes in GFP–Rab7-expressing cells demonstrates that disease mutants are similar to wild-type and distinct from Q67L Rab7. Approximately 40 cells were blindly scored for each Rab7 construct (see Supplementary Material, Fig. S6 for scoring examples). (D) FRAP of GFP–Rab7-positive vesicles in HeLa cells demonstrates that Rab7 disease mutants have a decreased rate of fluorescence recovery compared with wild-type. As expected, constitutively active Rab7 (Q67L) shows minimal fluorescence recovery due to the inability to hydrolyze GTP. (E) Representative time-lapse images of GFP–Rab7 vesicles before and after photobleaching. (F) FLAP of photoactivatable-GFP (PA-GFP)–Rab7-positive vesicles demonstrates that Rab7 disease mutants have a decreased rate of fluorescence loss compared with wild-type. As expected, constitutively active Rab7 (Q67L) shows minimal fluorescence loss due to the inability to hydrolyze GTP. (G) Representative time-lapse images of PA-GFP–Rab7 vesicles after photoactivation. Values indicate average fluorescence for at least 20 ROIs in at least 10 cells for each condition (*P = 1 × 10^{-15}). Error bars represent standard error of the mean.
GFP–Rab7 and regions of cytosol containing GFP–Rab7-positive vesicles were bleached with a high intensity laser. As recovery of fluorescence requires that the bleached GFP–Rab7 molecules dissociate from the membrane to allow insertion of unbleached Rab7 from the surrounding cytosol, the rate of fluorescence recovery represents flux through the Rab7 activity cycle (31). Rab7 disease mutants L129F and V162M showed a small but significant decrease in the rate of fluorescence recovery compared with wild-type, whereas the constitutively active Q67L mutant showed a nearly complete loss of fluorescence recovery due to the inability to hydrolyze GTP (Fig. 5D and E). These results indicate that disease-causing mutations in Rab7 cause a subtle decrease in the rate of membrane exchange.

Decreased FRAP could result from decreased membrane extraction or from impaired recruitment of unbleached Rab7 onto target membranes. To distinguish between these possibilities, we developed a complementary approach utilizing a phototactivatable GFP variant (PA-GFP) (32) fused to Rab7. As PA-GFP fluorescence is low until activation by brief high intensity laser stimulation, this construct permits selective activation of small regions of cytosol containing Rab7-positive vesicles. In activated regions of the cell, a majority of the activated Rab7 is membrane-bound and thus the fluorescence loss after photoactivation (FLAP) specifically measures the rate of extraction of Rab7 from its target vesicle membranes. Rab7 disease mutants L129F and V162M showed a decreased rate of fluorescence loss compared with wild-type Rab7, suggesting delayed membrane extraction (Fig. 5F and G). As expected, constitutively active Rab7 (Q67L) showed a markedly decreased rate of fluorescence loss due to the inability to hydrolyze GTP. Taken together, the FRAP and FLAP data suggest that Rab7 disease-causing mutants are impaired in membrane exchange specifically due to slowed extraction from their target membranes. Notably, the decreased rate of FRAP and FLAP in disease mutants was much less pronounced than in the Q67L mutant (Fig. 5D–G). Thus, despite a profound increase in the active fraction similar to that seen in the Q67L mutant, the net impact of disease-causing mutations in vivo is surprisingly subtle.

**GTP dissociation inactivates mutant Rab7**

Our data demonstrate that despite accelerated nucleotide exchange and a marked increase in the active fraction similar to the Q67L mutant (Fig. 3), Rab7 disease mutants have normal subcellular localization and only subtle defects in membrane extraction (Fig. 5). To reconcile these observations, we hypothesized that the excessive activation in mutant Rab7 is counterbalanced by unregulated, hydrolysis-independent termination of activity mediated by accelerated GTP dissociation (Fig. 2A). To test this, we generated compound mutants containing both the Q67L mutation (which inactivates the catalytic site) and a disease-causing mutation (either L129F or V162M). We predicted that conversion from GTP-bound, active Rab7 to inactive Rab7 through GTP dissociation would rescue the function of these catalytically dead mutants. Although transfected GFP–Rab7 Q67L showed vesicular clustering in the majority of cells, the phenotype was largely reversed by introducing the disease-causing mutations to the Q67L background (Fig. 6A and B, see Supplementary Material, Fig. S6 for scoring examples). To further demonstrate reversal of the Q67L phenotype in compound mutants, we performed FRAP assays to follow the extraction of the compound mutants from membranes. We found that the Rab7 compound mutants largely rescued the FRAP defect seen in the Q67L mutant alone, suggesting that the Rab7 disease-causing mutations increase GTP dissociation and lead to GTPase-independent membrane cycling of Rab7 in vivo (Fig. 6C). These results further indicate that GTPase deficiency cannot account for the defects in disease mutants, because these mutations are able to reverse the phenotype associated with a pure GTPase defect. Furthermore, these data demonstrate that disease mutants are not dependent on GTP hydrolysis for inactivation as is the case for nearly all Rab GTPases. Together with our GFP exchange assays, our results indicate that Rab7 mutations lead to misregulation of both activation of Rab7 by nucleotide exchange and inactivation of Rab7 by GTP dissociation. Therefore, GTP binding and membrane cycling of Rab7 mutants occur independent of the action of the normal regulatory controls that provide spatial and temporal specificity to Rab7 function.

**DISCUSSION**

In this study, we characterized the structural, biochemical and cell biological consequences of mutations in the small GTPase Rab7 that cause the dominantly inherited axonal degeneration CMT2B. Examination of the crystal structure of the L129F Rab7 mutant revealed alteration of the nucleotide binding pocket but no significant alteration to the catalytic site. We demonstrated that despite rapid GTP dissociation and re-association, GTPase activity in disease mutants is not significantly reduced. We showed that disease mutations result in an increase in the active fraction of Rab7 and a corresponding increase in binding to a subset of effector proteins. In addition, we demonstrated that increased activation in disease mutants is due to unregulated nucleotide exchange and not due to a hydrolysis defect. Surprisingly, the cellular phenotype of mutant Rab7 is milder than expected given the prominent, unregulated GTP exchange and marked increase in the active fraction. To account for this, we documented that unregulated activation of Rab7 disease mutants is mitigated by unregulated inactivation. Thus, our data reveal how misregulation of multiple steps of the Rab7 activity cycle leads to the alteration of Rab7 activity. A previous publication suggested that Rab7 disease mutants lead to constitutive activation and a nearly complete loss of catalytic activity (21). However, such a severe alteration of activity would be predicted to have far-reaching effects on Rab7-dependent pathways. Indeed, overexpression of constitutively active Rab7 leads to developmental defects in *Drosophila* (33,34). Although Rab7 is ubiquitously expressed, disease mutations cause adult-onset, slowly progressive disease that is restricted to the neurons with the longest axonal projections. Our findings of subtle changes in Rab7 activity are consistent with this pattern of disease in which a slight underlying defect becomes pathological only in a subset of vulnerable neurons.
Unregulated Rab7 cycling and accumulation of activated Rab7

Almost all Rab GTPases share two physiological properties, slow GDP dissociation and low intrinsic GTPase activity. These properties render Rabs, including Rab7, dependent on the positive and negative influences of regulatory GEF and GAP proteins. In Rab7 disease mutants, these two critical properties are absent, and Rab7 mutants are able to circumvent normal regulatory controls (Fig. 7). Specifically, we provide evidence that Rab7 mutants are able to become activated independent of GEF activity due to rapid, unregulated GTP exchange (Fig. 3), but this activation is counterbalanced by unregulated, GTPase-independent termination of activity (Fig. 6). The net effect of unregulated activation and inactivation is a subtle increase in the duration of association of active Rab7 with target membranes and an increase in the GTP-bound, active fraction (Figs. 3, 4, and 5).

Membrane cycling in mutant Rab7 is uncoupled from GTP hydrolysis

Although a previous report concluded that disease mutants have a GTPase defect (21), we demonstrate that this apparent defect is largely a reflection of increased GTP dissociation. Under conditions where GTP is provided in excess, the hydrolysis rate of disease mutants approaches that of wild-type Rab7 (Fig. 2C–E). As the physiological concentration of GTP (500 μM) is higher than the concentrations we used in our assays (35), we predict that in vivo, dissociation of GTP would be followed by re-association and subsequent hydrolysis. Indeed, the observation that the phenotype of disease mutants is somewhat altered by adding the Q67L mutation (Fig. 6A–C) provides indirect evidence that a modest amount of GTP hydrolysis does occur in disease mutants in vivo. Otherwise, adding the GTPase mutation to the disease mutant background would have no effect on their cellular function.

Figure 6. Rab7 disease mutants lead to GTPase-independent membrane cycling. (A) HeLa cells transfected with GFP–Rab7 were fixed and imaged. Rab7 Q67L,L129F or Q67L,V162M compound mutants largely rescue the abnormal vesicular clustering seen in the GTPase-deficient Q67L mutant. (B) Quantification of vesicular phenotypes in GFP–Rab7-expressing cells. Approximately 40 cells were blindly scored for each Rab7 construct (see Supplementary Material, Fig. S6 for scoring examples). (C) Compound mutants rescue the FRAP defect seen in the constitutively active Q67L mutant. Rab7 Q67L shows minimal fluorescence loss due to the inability to hydrolyze GTP. Membrane release and fluorescence recovery is restored by combining the Q67L mutation with the L129F or V162M disease mutations. Values indicate average fluorescence for at least 30 ROIs in at least 15 cells for each condition (P < 1 × 10^-5). Error bars represent standard error of the mean.
Rab7 mutations cause a quantitative but not qualitative change in interaction with effector proteins

Using LC-MS/MS, we demonstrate that disease-causing mutations do not qualitatively alter the complement of Rab7 interactors but cause quantitative changes in specific interactions (Fig. 4). This observation is consistent with our structural studies that reveal that the overall structure of mutant Rab7, and in particular the effector binding region, is unchanged from wild-type (Fig. 1). Specifically, we demonstrate significantly increased interaction of both Rab7 disease mutants with ORP1L, a well-characterized effector of active Rab7 that facilitates retrograde trafficking of late endosomes (36), and Vps13C, which also shows increased binding to the Q67L mutant and is likely a mediator of active Rab7 function. Vps13C is an as yet uncharacterized protein whose yeast homolog regulates trafficking to the vacuole (37). Our analysis also identified several previously unidentified potential interactors of Rab7 (Table 2). Of particular note are VapB, the FYVE containing-protein ANKFY1, and SPG21, which localize to membranes and potentially play a role in vesicular transport (38–40). A recent study elegantly demonstrated a role for VapB and VapA in regulating the cholesterol-dependent microtubule trafficking of Rab7-positive late endosomes (41). High cholesterol levels on the cytosolic face of vesicles activate ORP1L leading to stable recruitment of dynein, whereas low cholesterol levels allow the extraction of motor proteins from Rab7–RILP complexes by VapA and B. Our data suggest that misregulation of the Rab7 activity cycle in disease mutants may perturb such carefully orchestrated vesicular trafficking pathways.

Notably, two of the novel Rab7 interacting proteins we identified have been implicated in human diseases affecting the nervous system. VapB mutations cause a familial type of amyotrophic lateral sclerosis (ALS8) (42), and SPG21/maspardin mutations cause spastic paraplegia 21 (43). In addition, mutations in previously known Rab7 interactors have been implicated in multiple neurological diseases: REP-1 in choroideremia (44,45), GDI in X-linked mental retardation (46), p1500glued in distal spinal muscular atrophy (47), βIII spectrin in spinocerebellar ataxia 5 (48) and RILP as a gene deleted in Miller–Diecker syndrome (49). These results reveal a nexus of Rab7-associated proteins involved in human neurological disease and suggest that neurons are particularly vulnerable to mutations that impair protein trafficking through the endo-lysosomal system. Furthermore, the frequency with which function of the endo-lysosomal system is disrupted in familial and sporadic neurodegenerative diseases suggests overlapping mechanisms of pathogenesis, as has been suggested previously (50).

Functional consequences of Rab7 mutations

Dominantly inherited neurodegenerative diseases are typically attributed to gain-of-function mechanisms. At present, prevailing hypotheses suggest that disease results from gain of a novel toxic function that is unrelated to the normal function of the mutant protein. For example, many neurodegenerative diseases are caused by mutations that disrupt protein folding leading to the formation of aggregates that are potentially neurotoxic. In other cases, a dominant-negative mechanism leads
to loss-of-function of the mutant protein and its associated complexes. Our elucidation of the molecular defect caused by mutations in Rab7 illustrates an alternative mechanism: toxic misregulation of native function. Although there is precedent for this mechanism underlying tumorigenesis, to our knowledge, this is the first example of this type of mechanism underlying neurodegenerative disease.

How might misregulation of Rab7 lead to axonal degeneration? Rab7 specifically regulates transport, docking and fusion of late endosomes, autophagosomes and lysosomes. As such, Rab7 plays an important role in determining the fate of endocytic vesicles by regulating their fusion and subsequent degradation by lysosomes. In cultured neurons, over-expression of dominant-negative Rab7 reduces the degradation of TrkA-containing signaling endosomes leading to increased trophic signaling and excessive neurite outgrowth (9). Misregulation of Rab7 function as seen in CMT2B may have the opposite effect, resulting in premature lysosomal degradation of endocytic vesicles. CMT2B is characterized by length-dependent axonal degeneration that most prominently affects pain sensation. Notably, there is significant clinical overlap between CMT2B and familial insensitivity to pain (HSAN5, OMIM 608654) caused by loss-of-function mutations in nerve growth factor-beta (NGF-β) and also congenital insensitivity to pain with anhydrosis (OMIM 256800), which is caused by loss-of-function mutations in the NGF-β receptor TrkA (51,52). The phenotypic similarity of CMT2B to these syndromes leads us to speculate that Rab7 mutations may cause premature degradation of TrkA-containing signaling endosomes with resulting attenuation of neurotrophic support and selective axonal degeneration in a length-dependent manner. Our results provide a framework for future work examining how Rab7 mutants influence signaling endosome dynamics and vesicular trafficking in cultured neurons and animal models.

MATERIALS AND METHODS

Determination of the structure of L129F Rab7

Full-length L129F Rab7 was produced and crystallized as described in Supplementary Material. Phases were calculated by MR using Phaser (53) as implemented in CCP4 suite of programs using the substrate-free structure of Rab7 (PDB ID 1VG8) as a search model. Maps calculated after one cycle of refinement by REFMAC5 could be bound, His-MBP-Rab7 proteins were treated as above except incubated in Buffer A containing 2 mM unlabeled GTP before the addition of excess unlabeled GDP. Following hydrolysis, nucleotides were eluted as above. Samples were spotted on polyetherimide (PEI) cellulose and resolved in NaH2PO4 (pH 3.4) for ~1 h. Signals for GTP and GDP were calculated using a PhosphorImager. The percentage of 32P-GTP hydrolyzed in each experiment was calculated by dividing the GDP signal by the total signal from GTP and GDP, taking into account that the specific activity of 32P-GDP is two-third that of 32P-GTP.

GTPase assay

His-MBP-Rab7 fusion proteins were bound to NiNTA beads as above followed by three washes with 1 M guanidine-HCl and three washes with Buffer A. Reactions were incubated with 30 μl of Buffer A containing 32P-GTP for 2 h on ice to load GTP. Hydrolysis was initiated by moving the reactions to 37°C for 2 h. In some reactions, 1000-fold excess unlabeled GTP was added to the reaction during hydrolysis (+excess unlabeled GTP condition). Following hydrolysis, nucleotides were eluted as above. Samples were spotted on polyetherimide (PEI) cellulose and resolved in NaH2PO4 (pH 3.4) for ~1 h. Signals for GTP and GDP were calculated using a PhosphorImager. The percentage of 32P-GTP hydrolyzed in each experiment was calculated by dividing the GDP signal by the total signal from GTP and GDP, taking into account that the specific activity of 32P-GDP is two-third that of 32P-GTP.

GTP exchange assays

For the cell-free exchange assay, recombinant MBP-His-Rab7 proteins were bound, treated with guanidine-HCl, and washed as above. To determine the maximum amount of 3H-GTP that could be bound, His-MBP-Rab7 proteins were incubated in Buffer A containing 0.1 μM 3H-GTP for 30 min at 37°C. Following washes, bound 3H-GTP was eluted and quantified as above. To determine the GTP exchange rate, His-MBP-Rab7 proteins were treated as above except incubated in Buffer A containing 0.2 mM unlabeled GDP before the addition of 3H-GTP. Following washes, Buffer A containing 3H-GTP was added, and the proteins were incubated at 37°C for 10 or 30 min. Samples were washed and eluted nucleotides was quantified as above. The ratio of the amount of 3H-GTP bound at 10 or 30 min to the maximum amount bound without GDP pre-incubation was calculated for wild-type, L129F and V162M Rab7. For the exchange assay from cell lysates, HEK293T cells were transfected with FLAG–Rab7, and cells were harvested 48 h post-transfection and lysed in IP buffer [20 mM HEPES, 10% glycerol, 0.5% Triton X-100, 150 mM NaCl, 2 mM MgCl2, 1 mM DTT and Complete Mini Protease Inhibitor Cocktail EDTA-free (Roche)]. Rab7 proteins were immunopurified using FLAG-M2 agarose.
containing 0.1 μM 3H-GTP for 10 min at 37°C. Following several washes, bound nucleotides were eluted and quantified as above.

LC-MS/MS protein identification
HEK293T cells were transfected with FLAG–Rab7 constructs and immunoprecipitated as above, and proteins were separated by SDS–PAGE and stained with SYPRO Ruby (Sigma-Aldrich). Bands were then excised, digested, processed and analyzed as described in Supplementary Material.

FRAP
For Figure 5, HeLa cells were plated in 35 mm cover slip-bottom dishes (MatTek) and transfected with GFP–Rab7 constructs. Live-cell imaging was performed 24 h post-transfection using a FluoView FV1000 Olympus laser scanning confocal microscope. Cells were imaged every 3 s for 15 s total using the Argon ion 488 nm laser (30 mW) at 1% excitation power to record the pre-bleach fluorescence levels. Small regions of the cytosol containing GFP–Rab7 vesicles were then bleached using the 488 nm laser at 100% power for 2 s. Recovery of fluorescence was monitored every 3 s for 225 s using the 488 nm laser at 1% power. Regions of interest (ROIs) were drawn around bleached Rab7 vesicles and the fluorescence intensity at each time point was calculated using Metamorph software. Fluorescence intensity values were exported to Microsoft Excel and fluorescence recovery curves from each condition were averaged and plotted. Pre-bleach fluorescence was set to 1 and the first post-bleach time point was set to 0 for each ROI. For FRAP of compound mutants (Fig. 6), cells were plated and transfected as above, and imaged using a Nikon TE2000 microscope with a C1Si confocal using the 488 nm laser (30 mW) at 1% excitation power to record the fluorescence intensity of GFP–Rab7 vesicles. Small regions were then activated using a 2 s pulse with the violet diode 405 nm laser (25 mW) at 100% power. Loss of fluorescence was monitored every 3 s for 150 s using the 488 nm laser at 1% power (at this power, unactivated PA-GFP fluorescence is undetectable). ROIs were drawn around activated Rab7 vesicles and the fluorescence intensity was plotted over time as in FRAP assays. The first post-bleach time point was set to 1 for each ROI. Fluorescence loss curves from each condition were averaged and plotted. See Supplementary Material, for additional methods.

SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS
We thank Andrew Gillis and Meghan Mitchell for help in generating purified Rab7 for crystallization, Chunxu Qu for help in statistical analysis, Jennifer Peters, Samuel Connell, and Haji Takano for help with FRAP experiments, and Natalia Nedelsky and Brett Winborn for helpful comments and critical review of the manuscript. We thank Vincent Timmerman, Jacques Neefjes, Zakaria Hmama, Jennifer Lippincott-Schwartz, Aimee Edinger and Cecilia Bucci for providing critical reagents. We thank the Hartwell Center Proteomics Core for protein identification by LC-MS/MS and the Hartwell Center Protein Production Core for generating recombinant Rab7 proteins. Author contributions: B.A.M. and J.P.T conceived of and designed the study. B.A.M. conducted the study. E.S. contributed to collection and interpretation of structural data. B.A.M. and J.P.T. wrote the manuscript with contributions from E.S.

Conflict of Interest statement. None declared.

FUNDING
Financial support was provided by training grant T32AG000255, the Dana Foundation and ALSAC (American Lebanese Syrian Associated Charities). Funding to pay the Open Access publication charges for this article was provided by ALSAC.

REFERENCES
1. Sasaki, T., Kikuchi, A., Araki, S., Hata, Y., Isomura, M., Kuroda, S. and Takai, Y. (1990) Purification and characterization from bovine brain cytosol of a protein that inhibits the dissociation of GDP from and the subsequent binding of GTP to smg p25A, a ras p21-like GTP-binding protein. J. Biol. Chem., 265, 2333–2337.
2. Rak, A., Pylipenko, O., Durek, T., Watzke, A., Kushnir, S., Brunsfeld, L., Waldmann, H., Goody, R.S. and Alexandrov, K. (2003) Structure of Rab GDP-dissociation inhibitor in complex with prenylated YPT1 GTase. Science, 302, 646–650.
3. Sato, Y., Fukai, S., Ishihata, R. and Nureki, O. (2007) Crystal structure of the Sec4p.Sec2p complex in the nucleotide exchanging intermediate state. Proc. Natl Acad. Sci. USA, 104, 8305–8310.
4. Ullrich, O., Stemmark, H., Alexandrov, K., Huber, L.A., Kaibuchi, K., Sasaki, T., Takai, Y. and Zerial, M. (1993) Rab GDP dissociation inhibitor as a general regulator for the membrane association of rab proteins. J. Biol. Chem., 268, 18143–18150.
5. Feng, Y., Press, B. and Wandinger-Ness, A. (1995) Rab 7: an important regulator of late endocytic membrane traffic. J. Cell Biol., 131, 1435–1452.
6. Bucci, C., Thomesen, P., Nicoziani, P., McCarthy, J. and van Deurs, B. (2000) Rab7: a key to lysosome biogenesis. Mol. Biol. Cell, 11, 467–480.
7. Harrison, R.E., Bucci, C., Vieira, O.V., Schroer, T.A. and Grinstein, S. (2003) Phagosomes fuse with late endosomes and/or lysosomes by extension of membrane protrusions along microtubules: role of Rab7 and RILP. Mol. Cell. Biol., 23, 6494–6506.
23. Romero Rosales, K., Peralta, E.R., Guenther, G.G., Wong, S.Y. and
21. Spinosa, M.R., Progida, C., De Luca, A., Colucci, A.M., Alifano, P. and
28. Stein, M.P., Feng, Y., Cooper, K.L., Welford, A.M. and Wandinger-Ness,
27. Mizuno, K., Kitamura, A. and Sasaki, T. (2003) Rabring7, a novel Rab7
transport to lysosomes.
Rab7 controls the endosomal trafficking and neurotrophic signaling of the nerve growth factor receptor TrkA. J. Neurosci., 25, 10930–10940.
10. Ceresa, B.P. and Bahr, S.J. (2006) Rab7 activity affects epidermal growth factor-epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. J. Biol. Chem., 281, 1099–1106.
11. Gutierrez, M.G., Munafó, D.B., Beron, W. and Colombo, M.I. (2004)
28. Stein, M.P., Feng, Y., Cooper, K.L., Welford, A.M. and Wandinger-Ness,
27. Mizuno, K., Kitamura, A. and Sasaki, T. (2003) Rabring7, a novel Rab7
Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. J. Cell Sci., 117, 2687–2697.
12. Jager, S.,ucci, T., Ueno, T., Kominami, E., Saftig, P. and
26. Cantalupo, G., Alifano, P., Roberti, V., Bruni, C. and Schiaivo, G. (2006) Rab7 and Rab control endocytic sorting along the axonal retrograde transport pathway. Neuron, 52, 293–305.
1046
25. Andres, D.A., Seabra, M.C., Brown, M.S., Armstrong, S.A., Smeland, T.E., Cremers, F.P. and Goldstein, J.L. (1993) cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein. Cell, 73, 1749–760.
28. Stein, M.P., Feng, Y., Cooper, K.L., Welford, A.M. and Wandinger-Ness, A. (2003) Human VPS34 and p150 are Rab7 interacting partners. Traffic, 4, 754–771.
26. Cantalupo, G., Alifano, P., Roberti, V., Bruni, C. and Schiaivo, G. (2006) Rab7 and Rab control endocytic sorting along the axonal retrograde transport pathway. Neuron, 52, 293–305.
12. Jager, S.,ucci, T., Ueno, T., Kominami, E., Saftig, P. and
26. Cantalupo, G., Alifano, P., Roberti, V., Bruni, C. and Schiaivo, G. (2006) Rab7 and Rab control endocytic sorting along the axonal retrograde transport pathway. Neuron, 52, 293–305.
10. Ceresa, B.P. and Bahr, S.J. (2006) Rab7 activity affects epidermal growth factor-epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. J. Biol. Chem., 281, 1099–1106.
11. Gutierrez, M.G., Munafó, D.B., Beron, W. and Colombo, M.I. (2004)
28. Stein, M.P., Feng, Y., Cooper, K.L., Welford, A.M. and Wandinger-Ness,
27. Mizuno, K., Kitamura, A. and Sasaki, T. (2003) Rabring7, a novel Rab7
Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. J. Cell Sci., 117, 2687–2697.
12. Jager, S.,ucci, T., Ueno, T., Kominami, E., Saftig, P. and
26. Cantalupo, G., Alifano, P., Roberti, V., Bruni, C. and Schiaivo, G. (2006) Rab7 and Rab control endocytic sorting along the axonal retrograde transport pathway. Neuron, 52, 293–305.
10. Ceresa, B.P. and Bahr, S.J. (2006) Rab7 activity affects epidermal growth factor-epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. J. Biol. Chem., 281, 1099–1106.
11. Gutierrez, M.G., Munafó, D.B., Beron, W. and Colombo, M.I. (2004)
28. Stein, M.P., Feng, Y., Cooper, K.L., Welford, A.M. and Wandinger-Ness,
Spectrin mutations cause spinocerebellar ataxia type 5. *Nat. Genet.*, **38**, 184–190.

49. Cardoso, C., Leventer, R.J., Ward, H.L., Toyo-Oka, K., Chung, J., Gross, A., Martin, C.L., Allanson, J., Pilz, D.T., Olney, A.H. *et al.* (2003) Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller–Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3. *Am. J. Hum. Genet.*, **72**, 918–930.

50. Nixon, R.A., Yang, D.S. and Lee, J.H. (2008) Neurodegenerative lysosomal disorders: a continuum from development to late age. *Autophagy*, **4**, 590–599.

51. Einarsson, E., Carlsson, A., Minde, J., Toolanen, G., Svensson, O., Solders, G., Holmgren, G., Holmberg, D. and Holmberg, M. (2004) A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. *Hum. Mol. Genet.*, **13**, 799–805.

52. Indo, Y., Tsuruta, M., Hayashida, Y., Karim, M.A., Ohta, K., Kawano, T., Mitsubuchi, H., Tonoki, H., Awaya, Y. and Matsuda, I. (1996) Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. *Nat. Genet.*, **13**, 485–488.

53. Potterton, E., Briggs, P., Turkenburg, M. andDodson, E. (2003) A graphical user interface to the CCP4 program suite. *Acta Crystallogr. D. Biol. Crystallogr.*, **59**, 1131–1137.

54. Coot, K. (1994) A CCP4 density modification package. *Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography*, **31**, 34–38.

55. Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr. D. Biol. Crystallogr.*, **60**, 2126–2132.

56. Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S. *et al.* (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr. D. Biol. Crystallogr.*, **54**, 905–921.

57. Murshudov, G.N., Vagin, A.A. and Dodson, E.J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr. D. Biol. Crystallogr.*, **53**, 240–255.